NHS Mounjaro Criteria 2025: the phased rollout explained

What the 2025 NHS criteria actually require, and why they are drawn so tightly

NICE published its appraisal of tirzepatide (TA1026) in December 2024 and updated it in September 2025. The NHS England implementation that followed set a deliberate sequence: the highest-need patients first, broader groups later. For 2025, that means adults with a BMI of at least 40 who have four or more of a specific list of five conditions, type 2 diabetes, high blood pressure (hypertension), dyslipidaemia, obstructive sleep apnoea, or established cardiovascular disease. All five must be documented, not suspected.

The thresholds shift slightly for some ethnic backgrounds: for people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean heritage, BMI thresholds are 2.5 kg/m² lower throughout the phased rollout. So the 2025 cohort opens at BMI ≥37.5 rather than ≥40 for those groups. The tirzepatide NHS eligibility page sets out the ethnic-background adjustments in full.

The reasoning behind such a high starting threshold is resource sequencing, not clinical conservatism. NICE's appraisal confirmed Mounjaro's cost-effectiveness across a wide population (NICE TA1026 recommended it for adults with BMI ≥35 plus at least one comorbidity in the private and specialist setting) but NHS England chose to phase rollout by clinical urgency. Most people asking about Mounjaro in 2025 do not clear the current bar. That is worth knowing plainly before you spend time chasing a referral.

What changed in 2026, and where the phased rollout goes from here

The second cohort became available around June 2026: adults with BMI 35–39.9 who have four or more of the same five conditions. This is a meaningful expansion, though still a long way from the licence threshold of BMI ≥30 (or ≥27 with a weight-related condition) that private prescribers work to. A third cohort is expected around March 2027, dropping to three qualifying conditions at BMI ≥40.

Even within an eligible cohort, access is not automatic. From April 2026, GP practices may prescribe Mounjaro under the updated QOF contract, but participation is optional, and not every practice has opted in. Patients in areas where no local practice participates may still face a wait or a referral to a specialist weight-management service. The 2026 criteria update page tracks the latest cohort timings as they are confirmed.

NHS England also requires every patient on this pathway to engage with wrap-around support: structured diet guidance, physical-activity input, and behavioural change sessions. That is not a formality. If you meet the clinical threshold but cannot access the wrap-around programme locally, your GP cannot prescribe under this route. It is a genuinely joined-up pathway, and a slow-moving one for many people. NHS England's weight-management injections page has the detail on what wrap-around care involves.

If the NHS threshold is out of reach right now: the private prescription route

Private prescribing follows the licensed criteria, not the NHS phased ones. A prescriber can assess anyone with a BMI of 30 or above, or 27 or above with a qualifying weight-related condition, a much wider population than the NHS currently serves. The prescription must still follow clinical assessment; there is no shortcut past that. But the process moves on a different timescale. How private Mounjaro prescriptions work covers the mechanics.

Cost is the honest trade-off. Eli Lilly raised Mounjaro's UK list price from September 2025; private prices since then typically range from around £149 to £375 per monthly pen, depending on dose and provider. What those figures often conceal is whether consultation fees, prescription charges and delivery are included, or whether those appear separately at checkout. A breakdown of what private Mounjaro actually costs works through the full picture, including what a single transparent price means in practice.

The pen itself lives in the fridge (the door shelf is a practical spot, visible each week) and a prescriber reviews your case before every repeat. That clinical check is not optional paperwork; it is how dose increases are handled safely and how any early side effects are caught. For anyone who qualifies on paper, the question is whether the clinical oversight model they choose reflects that seriousness. What to look for when comparing private Mounjaro providers sets out the things that matter beyond the headline price.

Making the decision: NHS wait or private prescription?

This is genuinely a personal call, and the right answer is different for different people. If you sit inside the 2025 NHS cohort and your GP practice is participating, pursuing the NHS route makes obvious sense, it is subsidised, it is clinically supervised, and it comes with structured support. Ask your GP directly whether your practice has joined the QOF scheme and whether you are currently coded with the qualifying conditions. What your GP needs to prescribe Mounjaro under the NHS contract explains the conversation to have.

If you fall outside the current NHS threshold (BMI below 40, fewer than four conditions, or simply in an area where the pathway has not opened) a private prescription through a GPhC-registered pharmacy is the legal alternative. Clinical assessment happens either way. A prescriber looks at your health history, current medications, BMI, and any relevant conditions before any prescription is written. How NHS Mounjaro criteria compare to the private licence thresholds sets the two frameworks side by side clearly.

If you want to understand your options (NHS or private) without any pressure, our prescribers review every consultation personally. Check your eligibility with a free consultation.